CompanyVERANasdaqBrisbane, CA

Vera Therapeutics, Inc.

Vera Therapeutics is a commercial-stage biotech company developing TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor for reducing proteinuria in adults with primary IgA nephropathy.

Stories only

SEC EDGAR ClinicalTrials.gov veratx.com

424B3Sep 25Latest SEC filing

Sep 15Latest story

September 2026

Vera's TRUTAKNA hits all endpoints in ORIGIN 3 final analysis for IgA nephropathy

Sep 15Regulatory decisionatacicept Vera Therapeutics, Inc.

August 2026

Vera Therapeutics reports Q2 2026 results after TRUTAKNA accelerated approval

Aug 10Quarterly updateatacicept Vera Therapeutics, Inc.

July 2026

Vera Therapeutics names new Chief Regulatory Officer

Jul 9PeopleVera Therapeutics, Inc.